IP Library Granted Patent US 7,261,880
Granted Patent B2
US 7,261,880 · App. 10/125,701 · Granted Aug 28, 2007

Methods of treating Syndrome X with aliphatic polyamines

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,261,880
App. No.
10/125,701
Granted
Aug 28, 2007
Kind
B2
Abstract

The invention relates to a method for treating Syndrome X, or inhibiting the onset of symptoms of Syndrome X in a patient, and includes administering a therapeutically effective amount of a salt of at least one alkylated and cross-linked polymer, or a copolymer thereof, the polymer salt formed as a product of the reaction of one or more polymers, or salts and copolymers thereof, having a repeat unit that is essentially: where n is a positive integer and each R, independently, is H or a C 1 –C 8 alkyl group; at least one aliphatic alkylating agent; and a cross-linking agent. Long term administration of the cross-linked polyamine salts of the invention increases HDL levels and decreases LDL levels in patients. The invention also provides for administration of the polymer salt colesevelam, in combination with an HMG-CoA reductase inhibitor; the combined administration is effective in further lowering serum total-cholesterol and LDL-cholesterol levels beyond that achieved by either agent alone.

Claims (2)

1. A method for treating Syndrome X in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of colesevelam or a pharmaceutically acceptable salt thereof, alone or in combination with an antihyperlipidemic agent; a plasma HDL-raising agent; an antihypercholesterolemic agent; an acyl-coenzyme A: cholesterol acyltransferase (ACAT) inhibitor; a cholesterol absorption inhibitor; a bile acid sequestrant anion exchange resin; an LDL (low density lipoprotein) receptor inducer; a fibrate; vitamin B 6 (also known as pyridoxine) or a pharmaceutically acceptable salt thereof; vitamin B 12 ; an anti-oxidant vitamin; an angiotensin II antagonist converting enzyeme inhibitor; or a platelet aggregation inhibitor.

2. A method for treating Syndrome X in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of sevelamer or a pharmaceutically acceptable salt thereof.

Assignments (2)
MERGER Recorded May 5, 2003
From: GELTEX PHARMACEUTICALS, INC.
To: GENZYME CORPORATION
Reel/Frame 014022/0197 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 23, 2002
From: BURKE, STEVEN K.; DONOVAN, JOANNE M.
To: GELTEX PHARMACEUTICALS, INC.
Reel/Frame 013111/0958 →